
Leo Pharma should be prepared to accept a substantial dip in earnings from the company’s psoriasis ointment Dovonex. After the generics company Sandoz, owned by Swiss company Novartis, launched a copy of the ointment on the US market in August, the Danish pharmaceutical company stands to lose up to half a billion DKK in turnover, according to Danish business daily Børsen.
IMS Health reports that Dovonex sold for 118.8 million dollars (DKK 710.4) in the 12-month-period ending May 2012. It is normal for generics manufacturers to conquer about 80 % of a market, when a drug goes of patent in the US.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app